Thrombosis and Haemostasis, Table of Contents Thromb Haemost 2009; 102(04): 688-693DOI: 10.1160/TH09-04-0266 Blood Coagulation, Fibrinolysis and Cellular Haemostasis Schattauer GmbH Long-term complications of medical patients with hospitalacquired venous thromboembolism John Fanikos 1 Department of Pharmacy, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA , Gregory Piazza 2 Cardiovascular Division, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA , Maksim Zayaruzny 3 Center for Outcomes Research, University of Massachusetts Medical School, Worcester, Massachusetts, USA , Samuel Z. Goldhaber 2 Cardiovascular Division, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA › Author Affiliations Recommend Article Abstract Buy Article Keywords KeywordsVenous thromboembolism - deep vein thrombosis - pulmonary embolism - postthrombotic syndrome - chronic thromboembolic pulmonary hypertension - medical patients - surgical patients - prophylaxis Full Text References References 1 Cohen AT, Tapson VF, Bergmann JF. et al. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet 2008; 371: 387-394. 2 U.S Department of Health and Human Services. Office of the Surgeon General. The Surgeon General’s Call to Action to Prevent Deep Vein Thrombosis and Pulmonary Embolism. Available at: http://surgeongen eral.gov/topics/deepvein/calltoaction/remarks_dvt.html Accessed February 10. 2009 3 The Joint Commission. National consensus standards for prevention and care of venous thromboembolism (VTE). Available at: http://www.jointcommis sion.org/PerformanceMeasurement/PerformanceMeasurement/VTE.htm Accessed April 22. 2008 4 Prandoni P, Lensing AWA, Cogno A. et al. The long-term course of acute deep vein thrombosis. Ann Intern Med. 1996 127. 1-7. 5 White RH. The epidemiology of venous thromboembolism. Circulation. 2003 107. I-4-I-8.. 6 Hansson PO, Sorbo J. Eriksson H. Recurrent venous thromboembolism after deep vein thrombosis. Incidence and risk factors. Arch Intern Med 2000; 160: 769-774. 7 Eberhardt RT, Raffetto JD. Chronic venous insufficiency. Circulation 2005; 111: 2398-2409. 8 Kahn SR, Ginsberg JS. Relationship between deep vein thrombosis and the postthrombotic syndrome. Arch Intern Med 2004; 164: 17-26. 9 Hoeper MM, Mayer E, Simonneau G. et al. Chronic thromboembolic pulmonary hypertension. Circulation 2006; 113: 2011-2020. 10 Anderson FA, Zayaruzny M, Heit JA, at al. Estimated annual numbers of US acute-care hospital patients at risk for venous thromboembolism. Am J Hematol 2007; 82: 777-782. 11 Geerts WH, Pineo GF, Heit JA. et al. Prevention of venous thromboembolism. The Seventh American College of Chest Physicians Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 338S-400S. 12 U.S Department of Health and Human Services. Overview of the Healthcare Cost and Utilization Project. Available at: http://www.hcup-us.ahrq.gov/over view.jsp Accessed February 10. 2009 13 U.S Department of Health and Human Services. Healthcare cost and utilization project (HCUP). Overview of the Nationwide Inpatient Sample (NIS). Available at: http://www.hcup-us.ahrq.gov/nisoverview.jsp Accessed February 10. 2009 14 Oster G, Tuden RL, Colditz GA. A cost-effectiveness analysis of prophylaxis against deep vein thrombosis in major orthopedic surgery. JAMA 1987; 257: 203-208. 15 Cohen AT, Agnelli G, Anderson FA. et al. The VTE Impact Assessment Group in Europe (VITAE). Thromb Haemost 2007; 98: 756-764. 16 Amin A, Stemkowski S, Lin J, at al. Thromboprophylaxis rates in US medical centers: success or failure?. J Thromb Haemost 2007; 05: 16101-16116. 17 Yu HT, Dylan ML, Lin J, at al. Hospitals’ compliance with prophylaxis guidelines for venous thromboembolism. Am J Health-Syst Pharm 2007; 64: 69-76. 18 Alikahan R, Cohen AT, Combe S. et al. Risk factors for venous thromboembolism in hospitalized patients with acute medical illness. Analysis of the MEDENOX study. Arch Intern Med 2004; 164: 963-968. 19 Khorana AA, Francis CW, Culakova E. et al. Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncol 2006; 24: 484-490. 20 Seddighzadeh A, Shetty R, Goldhaber SZ. Venous thromboembolism in patients with active cancer. Thromb Haemost 2007; 98: 656-661. 21 Handley AJ. Low dose heparin after myocardial infarction. Lancet 1972; 02: 623-624. 22 Warlow C, Beattie AG, Terry G. et al. A doubleblind trial of low doses of subcutaneous heparin in the prevention of deep-vein thrombosis after myocardial infraction. Lancet 1973; 02: 934-936. 23 Emerson PA, Marks P. Preventing thromboembolism after myocardial infraction: effect of low dose heparin or smoking. BMJ 1977; 01: 18-20. 24 Alikahan R, Cohen AT, Combe S. et al. Prevention of venous thromboembolism in medical patients with enoxaparin. A subgroup analysis of the Medenox study. Blood Coagul Fibrinolysis 2003; 14: 341-346. 25 Matta F, Singala R, Yaekoub AY. et al. Risk of venous thromboembolism with rheumatoid arthritis. Thromb Haemost 2009; 101: 134-138. 26 Cohen AT, Turpie AGG, Leizorovicz A. et al. Thromboprophylaxis with dalteparin in medical patients: which patients benefits?. Vasc Med 2007; 12: 123-128. 27 McCarthy ST, Turner J. Low dose subcutaneous heparin in the prevention of deep vein thrombosis and pulmonary emboli following acute stroke. Age and Aging 1986; 15: 84-88. 28 Sherman DG, Albers GW, Bladin C. et al. The efficacy and safety of enoxaparin versus unfractionated heparin for the prevention of venous thromboembolism after acute ischemic stroke (PREVAIL Study): an open-label randomized comparison. Lancet 2007; 369: 1347-1355. 29 Levine RL, LeClerc JR, Bailey JE. et al. Venous and arterial thrombosembolism in severe sepsis. Thromb Haemost 2008; 99: 892-898. 30 Geerts WH, Code KI, Jay RM. et al. A prospective study of venous thromboembolism after major trauma. N Engl Med 1994; 331: 1601-1606. 31 Paciaroni M, Ageno W, Agnelli G. Prevention of thromboembolism after acute spinal injury with lowdose heparin or low-molecular-weight heparin. Thromb Haemost 2008; 99: 978-980. 32 Heit JA, Mohr DN, Silverstein MD. et al. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: A population based cohort study. Arch Intern Med 2000; 160: 761-768. 33 White RH, Zhou H, Murin S. Death due to recurrent thromboembolism among young healthier individuals hospitalized for idiopathic pulmonary embolism. Thromb Haemost 2008; 99: 683-690. 34 Prandoni P, Lensing AWA, Cogo A. et al. The longterm clinical course of acute deep vein thrombosis. Ann Intern Med 1996; 125: 1-7. 35 Pengo V, Lensing AWA, Prins MH. et al. For the Thromboembolic Pulmonary Hypertension Study Group. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med 2004; 350: 2257-2264. 36 Sullivan SD, Davidson BL, Kahn SR. et al. A costeffectiveness analysis of fondaparinux sodium compared with enoxaparin sodium as prophylaxis against venous thromboembolism. Use in patients undergoing major orthopedic surgery. Pharmacoeconomics 2004; 22: 605-620. 37 Piazza G, Seddighzadeh A, Goldhaber SZ. Double trouble for 2,609 hospitalized medical patients who develop deep vein thrombosis; prophylaxis omitted more often and pulmonary embolism more frequent. Chest 2007; 132: 554-561. 38 MacDougall DA, Feliu AL, Boccuzzi SJ. et al. Economic burden of deep vein thrombosis, pulmonary embolism, and post-thrombotic syndrome. Am J Health-Syst Pharm 2006; 63 (Suppl. 06) S5-15. 39 Prandoni P, Lensing AW, Prins MH. et al. Belowknee elastic compression stockings to prevent the postthrombotic syndrome: a randomized, controlled trial. Ann Intern Med 2004; 141: 249-256.
